首页>投融资
Eledon Pharmaceuticals
IPO后其他轮次
Eledon Pharmaceuticals, Inc.于2004年3月26日在特拉华州注册成立。该公司是一家临床阶段的生物制药公司,专注于开发针对于前列腺癌和其他激素驱动的疾病的治疗的新的专有疗法。公司目前专注于其在最初的阉割性前列腺癌的治疗或CRPC,它的前列腺肿瘤细胞表达了被截断的雄激素受体的改变。
基本信息
-
公司全称Eledon Pharmaceuticals Inc
-
类型小分子药物研发商
-
产业领域医药研发/制造
-
公司人数15~50人
-
地址19900 MacArthur Boulevard Suite 550 Irvine California
-
联系电话1-949-2388090
-
邮箱caton@purecommunicationsinc.com
-
成立时间2004-01-01
投融资
-
2024-05-09IPO后其他轮次5000万美元未透露
-
2023-05-01IPO后其他轮次1.85亿美元BVF PartnersArmistice Capital赛诺菲
-
2014-09-17上市9039.6万美元未透露
-
2013-05-15E轮3550万美元诺华Apple Tree Partners
- 加载更多
相关投融资企业
战略投资
Medic Life Sciences Inc是一家美国的生物技术公司,专注于开发创新的医疗设备和诊断技术。公司致力于改善患者的诊断和治疗体验,通过提供高效、便捷的医疗产品和服务,满足医疗市场的需求。其主要产品线包括医疗影像设备、诊断试剂和生物信息学工具等,通过不断的技术创新和市场拓展,为全球患者带来更好的医疗健康
收并购
Alderley Analytical is an independent Contract Research Organisation (CRO). We offer specialist bioanalytical services to support your drug development programmes, from discovery through to late stage clinical development, focusing on small molecules, large molecules, peptides, biologics and biomarkers.
Our biotech, pharma and CRO clients have discovered that keeping their bioanalysis with one provider means fewer laboratory transfers and no loss of bioanalytical knowledge of the molecule. By simplifying this process, it means less complications helping the rapid development of new drugs.
We take a flexible and responsive approach, using our collective expertise to develop novel bioanalytical methods and deliver your results on-time to the right quality. We also pride ourselves on excellent communication; you’ll find us easy to get hold of and we stay in touch, even if there’s no news to report.
As a GLP and GCP accredited laboratory, we can offer regulatory compliance where needed and are able to validate bioanalytical methods and deliver bioanalytical results to current FDA/EMA guidelines. Get in touch to discuss your bioanalysis requirements today.
Visit our website at www.alderleyanalytical.com for more information.
增发
Theriva Biologics, Inc.成立于1986年,是一家生物技术公司,专注于合成DNA为基础的疗法和治疗严重疾病的创新型疾病缓解药物的发展。该公司是一家多元化的临床阶段公司,开发旨在治疗高度未满足需求领域疾病的疗法。公司通过收购VCN Biosciences,SL进入肿瘤学领域,VCN Biosciences,SL开发了一种新的溶瘤腺病毒平台,设计用于静脉、玻璃体内和抗肿瘤递送以触发肿瘤细胞死亡,改善共同给药的癌症疗法对肿瘤的获取,并促进患者免疫系统产生强大而持续的抗肿瘤反应。